{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:02:51Z","timestamp":1776805371232,"version":"3.51.2"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ncl.2025.11.005","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:26:54Z","timestamp":1769516814000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuro-Ophthalmic Complications of Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"44","author":[{"given":"Catherine R.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagham","family":"Al-Zubidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2025.11.005_bib1","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-15-2569","article-title":"Molecular pathways: immune checkpoint antibodies and their toxicities","volume":"22","author":"Cousin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ncl.2025.11.005_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad169","article-title":"Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity","volume":"5","author":"Farina","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.ncl.2025.11.005_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2025.11.005_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ncl.2025.11.005_bib8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ncl.2025.11.005_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"10.1016\/j.ncl.2025.11.005_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ncl.2025.11.005_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.ophtha.2020.05.003","article-title":"Immune checkpoint inhibitor-associated optic neuritis","volume":"127","author":"Francis","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ncl.2025.11.005_bib12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after Anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology intelligent research in sight registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ncl.2025.11.005_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.774170","article-title":"Neurologic toxicity of immune checkpoint inhibitors: a review of literature","volume":"13","author":"Albarr\u00e1n","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ncl.2025.11.005_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.ncl.2025.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200058","article-title":"Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors","volume":"10","author":"Farina","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2025.11.005_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ncl.2025.11.005_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/01658107.2017.1368090","article-title":"Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management","volume":"42","author":"Hassanzadeh","year":"2018","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.ncl.2025.11.005_bib18","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.11.005_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/08820538.2023.2168494","article-title":"Immune checkpoint inhibitors and optic neuropathy: a systematic review","volume":"38","author":"Pietris","year":"2023","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ncl.2025.11.005_bib20","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1016\/j.radcr.2025.06.014","article-title":"Arteritic anterior ischemic optic neuropathy secondary to immune checkpoint inhibitors: a case report","volume":"20","author":"Alam","year":"2025","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.ncl.2025.11.005_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CJI.0000000000000394","article-title":"Eosinophilic vasculitis and arteritic anterior ischemic optic neuropathy associated with Anti-PD-L1 therapy","volume":"45","author":"Berry","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.ncl.2025.11.005_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/01658107.2019.1566385","article-title":"Isolated Abducens nerve palsy following pembrolizumab","volume":"44","author":"Jaben","year":"2020","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.ncl.2025.11.005_bib23","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1007\/s00415-024-12660-2","article-title":"Immune checkpoint inhibitors-associated cranial nerves involvement: a systematic literature review on 136 patients","volume":"271","author":"Pichon","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000524114","article-title":"Third cranial nerve palsy after monoclonal antibody therapy for lung cancer: a case report","volume":"13","author":"Missori","year":"2022","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.ncl.2025.11.005_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.642800","article-title":"Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy","volume":"12","author":"Valencia-Sanchez","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib26","article-title":"Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases","volume":"2021","author":"Li","year":"2021","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ncl.2025.11.005_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barr\u00e9 Syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"McNeill","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ncl.2025.11.005_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jamaneurol.2022.1824","article-title":"Association between a distinctive autoantibody-associated brainstem sensory syndrome and immune checkpoint inhibitors","volume":"79","author":"Damato","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib29","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital Inflammation--A case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ncl.2025.11.005_bib30","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/IOP.0000000000000509","article-title":"Inflammatory orbitopathy associated with ipilimumab","volume":"33","author":"Sheldon","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ncl.2025.11.005_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.669493","article-title":"Pembrolizumab-induced isolated cranial neuropathy: a rare case report and review of literature","volume":"12","author":"Bruno","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.11.026","article-title":"Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab","volume":"91","author":"Nasr","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ncl.2025.11.005_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-246443","article-title":"Giant cell arteritis associated with PD-1 inhibition","volume":"14","author":"Couette","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ncl.2025.11.005_bib34","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib35","article-title":"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma","volume":"20","author":"Narala","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ncl.2025.11.005_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ncl.2025.11.005_bib37","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ncl.2025.11.005_bib40","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000494078","article-title":"Lambert-Eaton Myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2018","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.ncl.2025.11.005_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ncl.2025.11.005_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.ncl.2025.11.005_bib43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2025.11.005_bib44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ncl.2025.11.005_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40123-020-00317-y","article-title":"Considerations for use of immune checkpoint inhibitors in cancer therapy for patients with Co-Existing thyroid eye disease","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ncl.2025.11.005_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ncl.2025.11.005_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ncl.2025.11.005_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ncl.2025.11.005_bib49","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ncl.2025.11.005_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"10.1016\/j.ncl.2025.11.005_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes","volume":"334","author":"Gill","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ncl.2025.11.005_bib52","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2025.11.005_bib53","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib54","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib56","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CJI.0000000000000360","article-title":"Impact of baseline corticosteroids on immunotherapy efficacy in patients with advanced melanoma","volume":"44","author":"Kartolo","year":"2021","journal-title":"J Immunother"},{"key":"10.1016\/j.ncl.2025.11.005_bib58","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fonc.2020.01677","article-title":"Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving Anti-PD-(L)1 blockade agents","volume":"10","author":"Riudavets","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ncl.2025.11.005_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051296","article-title":"Is timing of steroid exposure prior to immune checkpoint inhibitor initiation associated with treatment outcomes in melanoma? A population-based study","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:21:45Z","timestamp":1776802905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0733861925000891"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.11.005","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuro-Ophthalmic Complications of Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}